Somewhat Favorable Media Coverage Somewhat Likely to Impact Pfenex (PFNX) Stock Price

Press coverage about Pfenex (NYSEMKT:PFNX) has been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pfenex earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 50 out of 100, meaning that recent media coverage is somewhat likely to have an effect on the stock’s share price in the immediate future.

These are some of the news headlines that may have impacted Accern’s scoring:

Several equities analysts have recently issued reports on PFNX shares. Zacks Investment Research cut Pfenex from a “buy” rating to a “hold” rating in a research note on Saturday, July 15th. ValuEngine cut Pfenex from a “hold” rating to a “sell” rating in a research note on Saturday, June 3rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Pfenex in a research note on Thursday.

Shares of Pfenex (NYSEMKT:PFNX) traded up 2.90% on Friday, hitting $3.90. The stock had a trading volume of 78,917 shares. The company’s 50 day moving average price is $4.34 and its 200-day moving average price is $5.44. Pfenex has a 12 month low of $3.54 and a 12 month high of $11.35. The company has a market cap of $91.47 million, a P/E ratio of 25.49 and a beta of 4.65.

Pfenex (NYSEMKT:PFNX) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by $0.06. Pfenex had a negative net margin of 356.00% and a negative return on equity of 53.20%. The business had revenue of $3.03 million during the quarter, compared to analyst estimates of $3.10 million. During the same quarter in the prior year, the business earned ($0.43) earnings per share. The firm’s quarterly revenue was down 3.5% on a year-over-year basis. On average, analysts expect that Pfenex will post ($2.09) earnings per share for the current year.

In other news, Director Jason Grenfell-Gardner acquired 10,000 shares of the company’s stock in a transaction on Monday, June 12th. The shares were bought at an average price of $4.51 per share, with a total value of $45,100.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at approximately $45,100. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

TRADEMARK VIOLATION NOTICE: This news story was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at

Pfenex Company Profile

Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).

Insider Buying and Selling by Quarter for Pfenex (NYSEMKT:PFNX)

What are top analysts saying about Pfenex Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfenex Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit